Diagnamed Holdings Corp.
Diagnamed Holdings Corp. (DMED.CN) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Diagnamed Holdings Corp. (DMED.CN), covering cash flow, earnings, and balance sheets.
Diagnamed Holdings Corp. (DMED.CN) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Diagnamed Holdings Corp. DMED.CN financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | -$16082.00 | $77888.00 | $130883.00 | $54473.00 |
| SG&A Expenses | $131910.00 | $78355.00 | $139683.00 | $100677.00 |
| Operating Expenses | $148488.00 | $167039.00 | $270566.00 | $155150.00 |
| Total Costs & Expenses | $148488.00 | $167039.00 | $270566.00 | $155150.00 |
| Interest Income | $6427.00 | $0.00 | $42581.00 | $11108.00 |
| Interest Expense | $0.00 | $51450.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | -$2133.00 | $253498.00 | $147726.00 |
| EBITDA | -$148488.00 | -$169172.00 | -$126619.00 | $39864.00 |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | -$167039.00 | -$270570.00 | -$155150.00 |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | -$193679.00 | -$53583.00 | $143948.00 | $195012.00 |
| Income Before Tax | -$193679.00 | -$220622.00 | -$126618.00 | $39862.00 |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | -$253498.00 | -$148.00 |
| Net Income | -$193679.00 | -$220622.00 | -$126618.00 | $39862.00 |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.002 | -$0.003 | -$0.002 | $0.001 |
| Diluted EPS | -$0.002 | -$0.003 | -$0.002 | $0.001 |
| Weighted Avg Shares Outstanding | $80.05M | $80.05M | $80.05M | $80.05M |
| Weighted Avg Shares Outstanding (Diluted) | $80.05M | $80.05M | $80.05M | $80.05M |
Over the last four quarters, Diagnamed Holdings Corp. achieved steady financial progress, growing revenue from $0.00 in Q1 2024 to $0.00 in Q4 2024. Gross profit stayed firm with margins at N/A in Q4 2024 versus N/A in Q1 2024. Operating income totaled $0.00 in Q4 2024, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$148488.00. Net income rose to -$193679.00, with EPS at -$0.002. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan